Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 6,129

Document Document Title
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2010/129057A8
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical compositi...  
WO/2011/022489A2
The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine- specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer.  
WO/2011/001122A3
The invention relates to pyrazole derivatives of the general formula (I), where X is chlorine or fluorine. The invention also relates to a method for preparing same and to the therapeutic use thereof.  
WO/2011/019928A1
A modular system and method for producing urea from stranded natural gas includes removal of foreign particulate matter to obtain a substantially homogeneous gas. The gas is processed by controlling the quality of the stranded natural ga...  
WO/2010/065902A3
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal i...  
WO/2010/080795A8
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is (i), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...  
WO/2011/017201A2
Described herein is the DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluorome thyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonis...  
WO/2010/120138A3
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a –OH group and a carbonyl group are adjacent to each other on a benzene ring....  
WO/2010/112946A4
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...  
WO/2010/129057A3
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical compositi...  
WO/2011/001122A2
The invention relates to pyrazole derivatives of the general formula (I), where X is chlorine or fluorine. The invention also relates to a method for preparing same and to the therapeutic use thereof.  
WO/2010/132670A3
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...  
WO/2010/150255A1
Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. In another aspect of the invention ...  
WO/2010/143409A1
Disclosed are: a process for producing a salt of an optically active thiazolylalanine derivative which has a desired configuration by converting a thiazolylalanine derivative into a salt thereof and crystallizing a compound having one of...  
WO/2010/144055A1
The invention relates to compounds represented by the general formula (I): and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to 5; p is an integer from 0 to 4; R1 is selected from the group consisting of a hyd...  
WO/2010/110555A3
The present invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. The method of the present invention significantly shortens the time taken for optical transformation...  
WO/2010/112946A9
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...  
WO/2010/127558A1
Substituted benzoyl urea compounds, preparation methods and pharmaceutical uses thereof are disclosed. The compounds are shown by general structure formula (I), wherein R1, R2 and R3 are defined as those in the description. The compounds...  
WO/2010/128062A1
The invention relates to the use of O-imino-iso-urea compounds as source of radicals to polymerizable compositions comprising these O-imino-iso-urea and to new O-imino-iso-urea compounds. The O-lmino-isoureas compounds are compounds of t...  
WO/2010/122968A1
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...  
WO/2010/086878A3
The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta. Further, the present invention relates to processes of prepari...  
WO/2010/120138A2
The present invention relates to a salicylaldehyde chiral compound (chemical formula 1) and a naphtholaldehyde chiral compound (chemical formula 2), wherein a –OH group and a carbonyl group are adjacent to each other on a benzene ring....  
WO/2010/080795A3
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...  
WO/2010/112946A1
The invention relates to adamantane bisurea derivatives and their use. Adamantane bisurea derivatives are obtained by reaction of adamantane diamine with appropriate isocyanate, or by in situ preparation of adamantane isocyanate from ada...  
WO/2010/113848A1
Disclosed is a compound represented by formula (I) or the like, which serves as an agent for treatment of diseases that are induced by production, secretion and/or deposition of amyloid β protein. Specifically disclosed is a compound re...  
WO2010110555A2
The present invention relates to a method for obtaining optically pure amino acids, including optical resolution and optical conversion. The method of the present invention significantly shortens the time taken for optical transformation...  
WO/2010/062490A3
The present invention provides methods of forming carbamates, ureas, and isocyanates. In certain embodiments these methods include the step of reacting an amine with an ester-substituted diaryl carbonate to form an activated carbamate wh...  
WO/2010/062158A3
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...  
WO/2010/087318A1
Disclosed is a curable composition for a transfer material, which exhibits very good transferability in a nanoimprint process, while having a high selectivity between the dry etching rates by an argon gas and an oxygen gas. The curable c...  
WO/2010/081683A1
The present invention provides compounds (n-3 PUFA derivatives) of formula (I) that modulate conditions associated with cardiac damage, especially cardiac arrhythmias.  
WO/2010/080795A2
Provided is a complex of hydrogen peroxide and at least one compound represented by Formula (I): wherein X is ( ), -C(R3)3, -C=C(R3), -O(R3), -N(R3)2, or -S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, ...  
WO/2010/075636A1
The present invention provides in part a compound of Formula (I) or a pharmaceutically- acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea gr...  
WO/2010/046181A3
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...  
WO/2010/067005A1
The present invention relates to a method for preparing an allophanate, as well as to an allophanate and to a reduced viscosity polyisocyanate composition that contains the allophanate, intended for coating compositions, particularly pai...  
WO/2010/065902A2
A compound of Formula (I), a pharmaceutically acceptable salt, or solvate thereof, complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal i...  
WO/2010/063358A1
The invention relates to a method for producing a solution comprising urea urethanes and acting as a thixotropic agent, wherein at least two structurally different monohydroxy compounds are converted by an excess of toluylene diisocyanat...  
WO/2010/062158A2
The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4") in the cocktail preparation of...  
WO/2010/053128A1
Provided is a liquid crystal aligning agent capable of forming a liquid crystal alignment film the surface of which is rarely scratched or abraded when rubbed, and which exhibits excellent liquid crystal aligning properties and enables t...  
WO/2010/046181A2
The invention relates to substances for defoaming aqueous media. Said substances contain urea derivatives of formula (I) in the form of solid particles as defoaming agents. In formula (I), R1 is a hydrocarbon group comprising 4 to 30 car...  
WO/2010/035427A1
Disclosed is a urea compound represented by general formula (1). (In the formula, X1, X2 and X3 independently represent a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected fro...  
WO/2009/146539A8
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing 4-(aminome...  
WO/2010/024298A1
Disclosed is a compound represented by formula (I) [wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the description] or a pharmaceutically acceptable salt or solvate thereof.  
WO/2010/017470A1
The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composi...  
WO/2010/017060A1
This invention relates to compounds of the Formula (I):or a pharmaceutically acceptable salt, solvate, ester or isomer thereof, which is useful for the treatment of diseases or conditions mediated by LpxC.  
WO/2010/009508A1
A compound of Formula (A) wherein Z is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl, wherein the heteroaryl or substituted heteroaryl connected to a 2,4-dinito-6-(trifluoromethyl)phenyl ring via a carbon-carbon bond.  
WO/2008/083054A3
Novel β1 adrenoreceptor ligands that find use as imaging agents within nuclear medicine applications (e.g., PET imaging and SPECT imaging) are provided. Methods of imaging, including methods of imaging congestive heart failure, are also...  
WO/2009/145989A3
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described here...  
WO/2010/006085A1
The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprisi...  
WO/2009/130422A3
The present invention relates to the use of acylthiourea or acylurea derivatives of formula (I) for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, an...  

Matches 251 - 300 out of 6,129